Art Gilliland

Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ.

Delinea, Inc. is a provider of privileged access management solutions for modern, hybrid enterprises. The private company is located in the US and has subsidiaries in Germany. The American company's platform extends PAM by providing authorization for all identities, granting access to an organization's most critical hybrid cloud infrastructure and sensitive data to help reduce risk, ensure compliance, and simplify security. Delinea serves customers worldwide, ranging from small businesses to the world's largest financial institutions, intelligence agencies, and critical infrastructure companies.